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Abstract
Background: Polycystic ovarian syndrome (PCOS) is of frequent occurrence in Saudi females and is often associated
with obesity, insulin resistance, hypogonadotropic hypogonadism, and infertility. Since these features are also
associated with leptin receptor (LEP-R) deficiency, several studies have attempted to link LEP-R gene polymorphisms
to PCOS.
Methods: The purpose of this study is to assess the possible association of LEP-R gene polymorphism
(rs1137101) with the main obesity-linked metabolic parameters in Saudi female patients affected by PCOS. A
cohort of 122 Saudi female subjects, attending the outpatient’s clinics at Makkah, Saudi Arabia and diagnosed
with PCOS was investigated. Metabolic parameters in serum samples, including lipidogram, glucose, leptin,
ghrelin and insulin and obesity markers (BMI, W/H ratio, HOMA) were assayed and compared with values from
130 healthy female volunteers (controls).
The genotyping of rs1137101 polymorphism in the leptin receptor gene by amplification (PCR) followed by DNA
sequencing, was conducted in both groups (PCOS and controls).
Results: Waist/hip ratio (W/H ratio), leptin serum levels and triglycerides appeared to be associated with PCOS
but, aside from W/H ratio (AA s GG p = 0.009), this association also occurred for controls. No significant association in
the leptin gene polymorphic locus rs1137101 with PCOS was seen in the results of the present study. In the control
group, BMI, W/H ratio, leptin, Insulin, and HOMA-IR were significantly higher in the GG genotype compared to AA.
Conclusion: Despite previous suggestion about a relationship between rs1137101, serum leptin levels, and PCOS,
our studies do not show any statistical association and further investigations; possibly by also evaluating obese patients
should be needed to elucidate this issue better.
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Introduction
Leptin receptor (LEP-R; OB-R; CD295), which is
encoded by the LEPR gene, is a single-trans-membrane
domain protein receptor of the cytokine receptor family
[1] that binds the hormone leptin [2]. Cell membranes
of a variety of cells in different organs and tissues harbor
the LEP-R, signifying the role played by leptin in these
tissues [3–5]. Even in the hypothalamus, the LEP-R is lo-
cated in the cell membrane and is actively involved in
the control of hunger and thirst and influences sleep,
moods, and body temperature [6, 7]. Leptin, a polypep-
tide hormone, is a major player in regulating adipose tis-
sue mass through hypothalamus effects on hunger and
energy usage [6, 8]. Leptin binding to its receptor acti-
vates a series of chemical signals that influence hunger
and helps in the generation of a feeling of fullness (sati-
ety). Lean people generally have lower levels of leptin
compared to their obese counterparts, and female gen-
der, produce more leptin than their male counterpart
[9]. Interest in the role of leptin in the weight control
developed in the early ‘90s, and for over two decades
leptin is closely linked to body weight fluctuations
[10–13]. More recently it has become evident that
such weight-related alterations may be a consequence
of genetic variations in the LEP-R gene in the absence
of any qualitative or quantitative leptin abnormality
[14, 15]. In the LEP-R gene, several mutations are re-
ported that alter the normal functional capacity of the
LEP-R protein, resulting in an apparent “leptin recep-
tor deficiency,” hence preventing either the binding of
leptin to the receptor or the receptor from respond-
ing to the bond leptin. The consequences include ex-
cessive hunger, weight gain, and hypogonadotropic
hypogonadism [16]. Severe obesity due to excessive
eating (hyperphagia) begins in early childhood in
LEP-R deficiency disorders and the hypogonadotropic
hypogonadism, is caused by alleviated secretion of
hormones involved in direct sexual development. Affected
individuals experience the absence of or delay in puberty
and later may suffer from infertility disorder. In a recent
investigation, a statistically significant association was
found between polycystic ovarian syndrome (PCOS),
obesity and leptin, where the overweight and obese
women with PCOS had higher serum levels of leptin com-
pared with controls, though they have no association be-
tween PCOS and other adipokines, such as resistin and
adiponectin [17]. This should prompt the researcher to
deeply investigate this issue also in the influence of leptin
gene polymorphism. Several polymorphisms have been re-
ported in the LEP-R gene, which has been linked to a num-
ber of different disorders. One of the non-synonymous
polymorphisms rs1137101 (Gln223Arg), is linked to insulin
resistance, metabolic syndrome, dyslipidaemias, diabetes
mellitus, obesity, besides several cancers (breast, colorectal,
thyroid, prostate), preterm delivery, osteoarthritis, athero-
sclerosis, and ischemic heart disease [18–25]. We hypothe-
sized that LEP-R gene polymorphisms might be associated
with PCOS since the latter is associated with obesity, insu-
lin resistance, hypogonadotropic hypogonadism, and infer-
tility, all being common features of LEP-R deficiency [26].
Some associations have been reported, but the results have
frequently been contradictory.
Among the Saudi women, PCOS is of frequent occur-
rence, though the exact frequency is yet not known
(Babay Z; personal communication). In this study, the
distribution of genotype and allele frequencies of the
non-synonymous SNP rs1137101 (Gln233Arg) in the
normal healthy Saudi females and Saudi PCOS patients,
was investigated. We determined the effect of the differ-
ent genotypes on the demographic and metabolic pro-
files. In this paper, we also present our results of
association studies between rs1137101 polymorphism
and PCOS and the effect of the polymorphism on demo-
graphic and metabolic profile in healthy females and
those suffering from PCOS.
Methods
Study design and subjects
The study was conducted as a cross-sectional, case-
control study and included 130 Saudi females suffering
from PCOS, attending primary health clinics in Makkah,
Saudi Arabia, and 122 normal healthy females also at-
tending clinics for minor illnesses. The Institutional
Review Board (IRB) at Umm Al-Qura University, Makkah,
Kingdom of Saudi Arabia approved the study (IRB No.
235) and each female was required to sign an informed
consent form. Patients were attending the clinics of the
clinical co-investigator (MHD) and were diagnosed using
the criteria set by the Rotterdam consensus [27]. The con-
trols were age-matched (± 2 years SD), with no clinical,
biochemical or hormonal abnormalities. They also had
normal ultrasonic ovarian morphology and were having
regular ovulatory cycles (median 25–35 days). The inclu-
sion and exclusion criteria were as published earlier [28].
None of the individuals were on anti-diabetic or anti-
obesity drugs, glucocorticoids, or other hormonal therapy.
None of the females were smoking and performed daily
normal physical activity.
On a specific day, each patient and control was asked
to attend the clinic following overnight fasting. The
weight (Kg), height (cm), waist circumference and hip
circumference were measured in the standing position
and used to calculate the body mass index (BMI) (Kg/
cm2) and waist-hip ratio (WHR).
Blood and serum samples
Venous peripheral blood samples were withdrawn fol-
lowing an overnight (12 h) fast. Fasting blood (2 ml)
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were collected into chilled (+ 4 °C) tubes containing 1.2
mg EDTA and aprotinin (500 KIU/ml, Trasylol, Bayer
Corp., Leverkusen, Germany) for total ghrelin levels and
2ml were drawn in fluoride tubes (gray top) for glucose
estimation and 2 ml were collected in plain tubes for the
biochemical analysis. All samples were immediately cen-
trifuged, and the serum or plasma was stored at − 80 °C
until further analysis. A whole blood sample collected in
EDTA tubes was used to obtain genomic DNA using
Gentra Systems Kit (Minneapolis, MN, cat # D5500).
Estimation of biochemical and hormonal parameters
Blood serum was used to determine the lipids (cholesterol,
triglycerides, high-density lipoprotein [HDL-C] and low-
density lipoprotein [LDL-C]), applying enzymatic methods
using commercial kits (Boehringer Mannheim). Estima-
tion of leptin, ghrelin and insulin were conducted fol-
lowing the methods presented in Daghestani et al.
[28], The homeostatic model assessment insulin resist-
ance (HOMA-IR) and insulin secretion were calculated
using the following formulas: HOMA-IR = Fasting serum
insulin (μU/ml) × Fasting plasma glucose (mmol l-1)/22.5),
where FI is fasting insulin and G is fasting glucose.
Genotyping of rs1137101 polymorphism in leptin receptor
gene by DNA sequencing
The DNA fragment containing the exon 6 of LEP-R
gene was amplified by polymerase chain reaction (PCR)
using the following primers: sense primer (5′- TATA
GGCCTGAAGTGTTAGAAG-3′) and antisense primer
(5′- CCCATATTTATGGGCTGAACT-3′). The condi-
tions for PCR amplification were: initial denaturation
step at 95 °C for 15 min, followed by denaturation at
95 °C for 1 min for 34 cycles, annealing at 55 °C for
60 s, and DNA extension for 1 min at 72 °C, and final
extension for 10 min at 72 °C. The PCR product was
checked for purity and size on agarose gel electro-
phoresis and was subjected to DNA sequencing, ap-
plying an ABI Big Dye Terminator protocol using ABI
3100 Avant Genetic Analyzer.
Statistical analysis
Data for each female was entered on Excel spreadsheets
and subjected to routine analysis using SPSS (Statistical
Package for the Social Science, v22, Inc., Chicago, IL,
USA). For each parameter mean ± SEM were obtained
and results from different groups were compared using
Student’s t-test or a Mann-Whitney U-test as appropri-
ate. The patients and controls were grouped according
to their genotypes, and the values of anthropometric,
biochemical and hormonal parameters were calculated
in each group and compared using a paired two-tailed
Students ‘t’ test, separately in patients and controls.
For all comparisons p < 0.05 was considered statisti-
cally significant.
Genotypes were manually counted in the PCOS and
controls and those grouped as normal weight and obes-
ity (PCOS and controls). The comparison of the geno-
type and allele frequencies in the patients and controls
was obtained using the Statistical computational soft-
ware available at Institute fur Humangenetik (URL:
https://ihg.gsf.de/cgi-bin/hw/hwa1.pl). The odds ratio
(OR), 2. 5-97.5% confidence intervals (CI), Chi-square
(χ2) and p-value were calculated for each genotype and
allele to compare the significance of the difference be-
tween the patients and controls. To assess the use of sta-
tistics in our samples and for independent samples
evaluated with a t-test, the Cohen’s D test was used, cal-
culated as the mean difference between two groups di-
vided by the pooled standard deviation, according to:
Cohen0sd ¼ M1þM2ð Þ=SDpooled
Effect sizes (ES) can also be interpreted in terms of the
percent of non-overlap of the treated group’s scores with
those of the untreated group. In few words, the effect
size gives the probability that a person selected at ran-
dom from the group who were treated will have a higher
score than a person picked at random from the control
group. Furthermore, Hedges’s g values were computed
from Cohen’s d. The parameter is an inferential measure,
which is normally computed by using the square root of
the mean square error (SEM) from the analysis of vari-
ance testing for differences between the two groups. To
measure interaction, the ES correlation was also com-
puted from Cohen’s d. In this case, the R-square value is
the percentage of variance in the dependent variable that
is accounted for by membership in the independent
variable groups. For a Cohen’s d value of 1.0, the
amount of variance in the dependent variable by
membership in the treatment and control groups is
0,2% and r = 0.447 [29, 30].
Results
The study group included 122 healthy females of Saudi
origin and another group of 130 women who were diag-
nosed as suffering from PCOS. The demographic, meta-
bolic and hormonal parameters in the two groups were
as presented in Daghestani et al. (28). The two groups
matched for their ages and BMI but showed a significant
difference in the W/H ratio, where the PCOS patients
had a significantly higher ratio compared to the control
group. Among the lipid parameters, all parameters were
elevated in the PCOS compared to the control group
except HDL, which was significantly lower. Insulin,
glucose, and HOMA-IR were also significantly ele-
vated in the PCOS, but leptin, ghrelin, and HOMA-S
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were not different significantly when compared with
the control group.
The genotype and allele frequencies of rs1137101 in
the control group were compared to the results in the
PCOS patients. Table 1 presents the frequencies and
shows that there were no significant differences between
the two groups.
To determine differences in the genotype and allele
frequencies in patients who were normal weight and
obese, the control and patients were separated into two
groups based on their BMI. Table 2 presents the geno-
type (AA, AG, GG) and allele (A and G) frequencies of
rs1137101 in the normal weight and obese PCOS pa-
tients compared to normal weight and obese controls.
The PCOS and control group were separated into
three groups based on the genotypes: AA, AG and GG
and the demographic and metabolic data were separately
calculated for each genotype. The results in the different
genotypes were compared, and the significance of the
difference in the results was recorded. In the control
group, BMI, W/H ratio, leptin, Insulin, and HOMA-IR
were significantly higher in the GG genotype compared
to AA. In the PCOS group statistically significant differ-
ences were observed for W/H ratio and leptin in the AA
Table 1 Comparison between the genotype and allele frequencies
of rs1137101 in PCOS patients and controls
PCOS patient Control OR CI χ2 P-value
Genotype frequency
AA 85 (76.16) 82 (71.66) Ref.
AG 29 (46.69) 23 (43.68) 1.21 0.65–2.27 0.38 0.539
GG 16 (7.16) 17 (6.66) 0.90 0.43–1.91 0.06 0.799
AG + GG 45 (34.6) 40 (32.7) 1.08 0.64–1.83 0.09 0.758
Allele frequency
A 199 (76.5) 187 (76.6) Ref.
G 61 (23.4) 57 (23.3) 1.00 0.66–1.51 0.00 0.976
Table 2 Comparison between the genotype and allele frequencies of rs1137101 in normal weight and obese PCOS patients and controls
Genotype/allele Control (N) Control (O) OR CI χ2 P-value
AA 42 (37.28) 40 (31.66) Ref.
AG 13 (18.44) 10 (24.68) 0.76 0. 30-1.95 0.30 0.581
GG 5 (2.28) 12 (4.66) 2.40 0.77–7.44 2.39 0.122
AG + GG 18 (31.0) 22 (35.4) 1.22 0.57–2.61 0.27 0.605
A 93 (80.1) 90 (72.5) Ref.
G 23 (19.8) 34 (27.4) 1.52 0.83–2.79 1.91 0.167
Genotype/allele Patient (N) Patient (O) OR CI χ2 P-value
AA 42 (38.40) 43 (37.89) Ref.
AG 12 (19.20) 17 (24.22) 1.38 0.59–3.24 0.56 0.454
GG 6 (2.40) 10 (4.89) 1.62 0.54–4.88 0.77 0.381
AG + GG 18 (30) 27 (38.5) 1.46 0.70–3.04 1.05 0.305
A 96 (80) 60 (42.8) Ref.
G 24 (20) 27 (19.2) 1.43 0.80–2.57 1.49 0.222
Genotype/allele Control (N) Patient (N) OR CI χ2 P-value
AA 42 (39.20) 42 (38.40) Ref.
AG 13 (18.59) 12 (19.20) 0.92 0. 37-2.25 0.03 0.860
GG 2 (2.20) 6 (2.40) 1.20 0. 34-4.23 0.08 0.776
AG + GG 15 (25.8) 18 (29.0) 1.00 0.45–2.18 0.00 1.000
A 97 (83.6) 96 (80.0) Ref.
G 15 (12.9) 24 (20.0) 1.05 0.55–1.99 0.03 0.870
Genotype/allele Control (O) Patient (O) OR CI χ2 P-value
AA 40 (32.66) 43 (37.86) Ref.
AG 10 (24.68) 17 (27.22) 1.58 0.64–3.85 1.02 0.311
GG 12 (4.66) 10 (4.89) 0.77 0. 30-1.99 0.28 0.596
AG + GG 22 (35.4) 27 (38.5) 1.14 0.56–2.31 0.13 0.714
A 90 (72.5) 103 (73.5) Ref.
G 34 (27.4) 27 (19.2) 0.95 0.55–1.64 0.03 0.856
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Table 3 Comparison of anthropometric, hormonal and lipid parameters and glucose in PCOS and control groups carrying different
genotypes of rs1137101
Parameter Group rs1137101 genotypes
Mean ± SEM
P-value
AA AG GG
BMI (kg/m2) PCOS 30.0 ± 0.75 31.0 ± 1.37 32.5 ± 1.99 AA vs. AG 0.491
AA vs. GG 0.162
GG vs. AG 0.543
Control 26.0 ± 0.72 29.4 ± 0.18 33.6 ± 2.07 AA vs. AG 0.018
AA vs. GG 0.000
GG vs. AG 0.181
W/H ratio PCOS 0.84 ± 0.01 0.87 ± 0.01 0.91 ± 0.029 AA vs. AG 0.064
AA vs. GG 0.009
GG vs. AG 0.05
Control 0.75 ± 0.01 0.76 ± 0.17 0.78 ± 0.016 AA vs. AG 0.040
AA vs. GG 0.119
GG vs. AG 0.252
Cholesterol (mmol/L) PCOS 4.5 ± 0.11 4.35 ± 0.22 4.5 ± 023 AA vs. AG 0.530
AA vs. GG 1.00
GG vs. AG 0.676
Control 3.57 ± 0.06 3.79 ± 0.11 3.72 ± 0.121 AA vs. AG 0.180
AA vs. GG 0.313
GG vs. AG 0.718
Triglyceride (mmol/L) PCOS 1.05 ± 0.05 1.34 ± 0.08 1.2 ± 0.14 AA vs. AG 0.003
AA vs. GG 0.147
GG vs. AG 0.464
Control 0.83 ± 0.04 0.92 ± 0.09 0.96 ± 0.09 AA vs. AG 0.001
AA vs. GG 0.209
GG vs. AG 0.764
HDL (mmol/L) PCOS 1.12 ± 0.35 0.98 ± 0.03 1.07 ± 0.08 AA vs. AG 0.040
AA vs. GG 0.613
GG vs. AG 0.248
Control 1.29 ± 0.03 1.30 ± 0.07 1.12 ± 0.06 AA vs. AG 0.080
AA vs. GG 0.061
GG vs. AG 0.248
LDL (mmol/L) PCOS 2.55 ± 0.09 2.56 ± 0.15 2.63 ± 0.16 AA vs. AG 0.978
AA vs. GG 0.678
GG vs. AG 0.771
Control 1.69 ± 0.07 1.81 ± 0.15 1.68 ± 0.13 AA vs. AG 0.101
AA vs. GG 0.989
GG vs. AG 0.570
Leptin PCOS 28.2 ± 1.67 29.8 ± 3.29 38.4 ± 5.93 AA vs. AG 0.634
AA vs. GG 0.027
GG vs. AG 0.179
Control 22.2 ± 1.78 29.3 ± 5.0 40.0 ± 6.48 AA vs. AG 0.060
AA vs. GG 0.000
GG vs. AG 0.194
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vs. GG (p = < 0.05), in the PCOS, while in the AA vs. AG
genotypes, the triglyceride levels were higher (p = 0.003).
However, this genotype also associated with leptin and
triglyceride level in the controls (p = 0.01). The results
are presented in Table 3.
Subject’s distribution and statistical power were
assessed by further tests, by evaluating the effect size
on our sampling procedures. Table 4 describes the
outputting results. Most of the comparisons (78.8%)
showed a small non-overlapping percentage, calcu-
lated on Cohen’s d-effect size and demonstrate that
for certain parameters (e.g., triglycerides SNP rs1137101
AA vs. AG) Cohen’s d and its co-related Gates’ delta and
Hedges g, showed the same population overlapping be-
tween PCOS subjects and controls (see Table 4, 29.59 and
30.26%, respectively), assessing the sampling process per-
formed in the study. Yet, this correspondence has not
been observed for leptin (SNP rs1137101 AA vs. GG, see
Table 4), what might also explain our negative data for
leptin polymorphism association with PCOS, inducing
out further research to improve cases and controls
recruitment.
Discussion
The LEP-R gene has been extensively investigated in sev-
eral populations, and the association has been investi-
gated with a number of diseases including obesity,
preterm delivery, recurrent spontaneous abortion and
different cancers [16–25]. Several polymorphisms have
been investigated, and rs1137101 has been commonly
associated with several disorders. Our results showed
that LEP-R gene SNP rs1137101 do not show any associ-
ation with obesity either in the healthy normal Saudi
population or the females suffering from PCOS. The
only important association was reported for the waist/
hip ratio (W/H ratio), while the association with lipido-
gram and leptin was also observed for non-PCOS indi-
viduals. Reports showing possible leptin-W/H ratio
associations were suggested either for healthy people or
several disorders and aging [31–34].
Table 3 Comparison of anthropometric, hormonal and lipid parameters and glucose in PCOS and control groups carrying different
genotypes of rs1137101 (Continued)
Parameter Group rs1137101 genotypes
Mean ± SEM
P-value
AA AG GG
Ghrelin PCOS 0.39 ± 0.02 0.38 ± 0.16 0.32 ± 0.13 AA vs. AG 0.622
AA vs. GG 0.053
GG vs. AG 0.239
Control 0.49 ± 0.01 0.39 ± 0.03 0.30 ± 0.02 AA vs. AG 0.005
AA vs. GG 0.000
GG vs. AG 0.042
Insulin (pmol/L) PCOS 110.8 ± 7.7 107.4 ± 10.77 92.60 ± 14.06 AA vs. AG 0.794
AA vs. GG 0.270
GG vs. AG 0.412
Control 66.7 ± 4.03 80.8 ± 7.33 95.4 ± 10.5 AA vs. AG 0.110
AA vs. GG 0.005
GG vs. AG 0.247
Fasting glucose PCOS 5.09 ± 0.06 5.07 ± 0.08 5.04 ± 0.143 AA vs. AG 0.828
AA vs. GG 0.723
GG vs. AG 0.874
Control 4.66 ± 0.05 4.63 ± 0.12 5.06 ± 0.12 AA vs. AG 0.522
AA vs. GG 0.002
GG vs. AG 0.012
HOMA-IR PCOS 3.61 ± 1.74 3.51 ± 1.85 3.04 ± 0.489 AA vs. AG 0.788
AA vs. GG 0.274
GG vs. AG 0.448
Control 2.04 ± 0.13 2.44 ± 0.24 3.16 ± 0.37 AA vs. AG 0.139
AA vs. GG 0.002
GG vs. AG 0.110
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However, despite some recent conclusions on obese
patients [35, 36] and cancer [35, 37], no report was yet
published about the possible association of the SNP
rs1137101 at the leptin gene. Recent reports showed that
obesity should play a major role in the pathogenesis of
PCOS through the insulin, leptin and endocannabinoid
receptor, and by an association between insulin receptor
polymorphism and PCOS was observed [38]. Further-
more, an association of the leptin gene SNPs (Gln223Arg
and Pro1019Pro) with PCOS was recently reported in a
Korean population [39]. Despite this interesting evidence,
our data seem to confirm previous reports showing no
association between leptin gene single nucleotide poly-
morphism and PCOS, though PCOS is frequently associ-
ated with insulin resistance and obesity and these
conditions are linked to leptin resistance and expression
in the leptin receptor. Past analyses demonstrated that pa-
tients diagnosed with PCOS did not show any mutation of
the leptin coding exons, while the amino acid variants in
exon 2, 4 and 12, through a single-stranded conform-
ational polymorphism (SSCP) analysis, followed by se-
quencing, did not show any association between leptin
and PCOS [40], suggesting that much more insightful evi-
dence should be gained by further studies. The results of
this study highlight an important point, i.e. the poly-
morphic change resulting from the substitution of an A by
G, changing the codon, CAG to CGG, and replacing Gln,
a neutral amino acid by Arg, a basic amino acid, brings
about an effect thereby affecting the value of different an-
thropometric and biochemical parameters, both in normal
control and PCOS patients. The exact mechanism by
which these changes are brought about needs functional
and in-silico studies, whereby the mechanism of leptin-
LER-R interaction can be evaluated.
Finally, since our study did not show any statistical as-
sociation between rs1137101 and PCOS, further investi-
gation, possibly by also evaluating obese patients should
be needed to elucidate this issue better.
Conclusion
In conclusion, the results of this study do not show any
association between rs1137101 in the LEP-R gene and
PCOS development in Saudi females. Association was
observed with W/H ratio, leptin level and the lipidogram
in the PCOS females. However, the association with lep-
tin and lipidogram was also observed in the non-PCOS
females. Further studies are warranted to determine the
mechanism of interaction between leptin and its recep-
tor, which results when Gln, a neutral amino acid, is re-
placed by Arg, a basic amino acid. Furthermore, whether
there is any association between other SNPs in LEP-R
and PCOS development in Saudis requires further
detailed studies.
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